UHPLC analysis of challenging MAbs

May 8, 2020

Sponsored Content - EU

This application note using YMC-Triart Bio C4 shows a robust separation at high temperatures of 3 commercially available MAbs: Ofatumumab, Palivizumab, and Panitumumab.